Leveraging the power of surface chemistry, native membrane protein biochemistry, biosensing, artificial intelligence and machine learning to provide 

a Disruptive Point-of-Care Test for Disease Diagnostics & Therapy Monitoring

Image de Fusion Medical Animation
Image BSD.jpg
Laboratory Scientist
ACS Omega cover.jpg
Image de CDC
Male Scientist
Pharmacien aider femme âgée
Image de ThisisEngineering RAEng
Image de CDC
Image de National Cancer Institute
Pipetting Samples
Scientist Pipetting


A Disruptive Technology for Medical Diagnostics, therapy monitoring and Point-of-care testing (POCT).

Biosensing Diagnostics ™ offers disruptive diagnostic solutions of high specificity for infectious and chronic diseases, while respecting regulatory standards. Our approach combines patented technologies in:

 - Development of innovative antibodies against native membrane proteins (biomarkers)

- Magnetic particles (Inactivation and concentration of the biological sample)

- Surface Plasmon Resonance (portable)

- Innovative surface chemistry (sensitivity and specificity of fixation)

- A digital hub using Artificial Intelligence and Machine Learning (Analysis and Interpretation)

Our technological solution is fast, easy to use, sensitive & versatile (Portable based on SPR and assisted by AI / ML).

Image Covid_edited.jpg


A commercialization of patented technologies generated by the funded EU Consortium Cordial-S

The goal of Biosensing Diagnostics ™ is to commercialize the result produced by a consortium led by Sabine Szunerits (Chemistry Professor) at the University of Lille in France which has been awarded €2.3 million ($2.7 million) to develop a surface plasmon resonance-based device for detecting SARS-CoV-2 at the point of care. The effort, called "Coronavirus diagnostics using surface plasmon resonance," or CorDial-S, will pave the way to the commerialization of POCT for infectious diseases (such as Covid-19 and other respiratory indications) in addition to chronic diseases. Biosensing Diagnostics ™ was selected by EURASANTE committee and is now part of Lille Incubator.






Scientific Advisor

25 years experience. Professor in Chemistry at University of Lille and carring out her research at IEMN, Lille. Her background is in biosensing notably focusing on surface chemistry to obtain site-oriented receptor linkage for sensitive and selective sensor. She is Editor-in-Chief of Sensors and Diagnostics, RSC journal. She got awarded the medaille d’Argent du CNRS in 2018 for her contribution to innovative sensing and nanomedicine including what paves the way to Biosensing Diagnostics™. In fact, Sabine was the coordinator of Cordial-S a EU Consortium that could develop Point-of-care testing (POCT) for COVID-19 diagnostic. Her work was also instrumental for other unmet medical needs.

JAWHARI Anass.jpg


Founder & CEO

20 years of experience as a researcher in biotechnology (10 years in the academic sector as PhD and HDR/ PhD supervisor in France, Germany, United States, and 10 years in biotech / Pharma). 8 years as Chief Scientific Officer, SME Board Member. He selected Antibodies against cancer receptors and against CNS targets. He has also developed drug candidates and vaccines.  He was involved in Diagnostic projects using ELISA, Mass spectrometry, RT-PCR and now SPR. He serves as Editorial Board Member of Nature, Methods. He worked as Business Executive and Advisor for Pharma companies. He was trained in Leading Business Schools (London BS/ Entrepreneurship, Harvard BS/ Strategy, MIT/ Biotech Finance, Wharton/ Marketing, Berkley/ Market Data Analytics and Maryland Univ/ Leadership). Dr. Jawhari is also HEC Paris Executive MBA (General Management, Major on Entrepreneurship and Biotech Innovation).

Réunion du conseil




Technology Advisor

He is Managing Director of AIT Austrian Institute of Technology and Visiting Professor at Nanyang Technological University Singapore. He graduated from the University of Konstanz in 1976 with a PhD degree in Biophysics after having completed an education in Physics at the Karlsruhe University of Technology. From 1980-1981, he was a Visiting Scientist at the IBM Research Laboratory in San Jose, California and the Institute Laue-Langevin in Grenoble, France, from 1981-1986 an Assistant Professor at the Technical University of Munich, Germany and in 1986 he joined the Max Planck Institute for Polymer Research in Mainz, Germany, as a group leader. From 1991-1999, Wolfgang Knoll was the Director of the Laboratory for Exotic Nanomaterials, hosted by the Institute of Physical and Chemical Research (RIKEN) in Wako/Japan and from 1992 to 2010, he was a Consulting Professor at the Department of Chemical Engineering at Stanford University. From 1993 to 2008, Wolfgang Knoll was the Director of the Max Planck Institute for Polymer Research. In 1998, he became a Professor of Chemistry (by courtesy) at the University of Florida in Gainesville, and in 1999, he was appointed Adjunct Professor by Hanyang University in Seoul, South Korea. Since 2008, Wolfgang Knoll is the Scientific Managing Director of the AIT Austrian Institute of Technology in Vienna and became a Visiting Professor of Nanyang Technological University in Singapore in 2009.

logo partners.png.jpg

Upcoming Events

  • BIO International Convention
    lun. 13 juin
    San Diego
    13 juin, 09:00 UTC+2 – 16 juin, 17:00 UTC+2
    San Diego, San Diego, Californie, États-Unis



HEC Paris Executive MBA

Founder & CEO

Biosensing Diagnostics 

310 avenue Eugène Avinée

Parc Eurasanté Ouest

59120 Loos, FRANCE


  • Facebook
  • Twitter
  • LinkedIn
Embryonic Stem Cells_edited_edited.jpg